ES2172939T3 - Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores. - Google Patents

Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.

Info

Publication number
ES2172939T3
ES2172939T3 ES98957267T ES98957267T ES2172939T3 ES 2172939 T3 ES2172939 T3 ES 2172939T3 ES 98957267 T ES98957267 T ES 98957267T ES 98957267 T ES98957267 T ES 98957267T ES 2172939 T3 ES2172939 T3 ES 2172939T3
Authority
ES
Spain
Prior art keywords
transmembrane
protein
antagonists
purinoceptors
new compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98957267T
Other languages
English (en)
Inventor
Nicholas Kindon
Premji Meghani
Stephen Thom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9704272A external-priority patent/SE9704272D0/xx
Priority claimed from SE9801397A external-priority patent/SE9801397D0/xx
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Application granted granted Critical
Publication of ES2172939T3 publication Critical patent/ES2172939T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula I o una sal del mismo: en la que Y es hidrógeno, alquilo C1-4, alquilo C1-4 opcionalmente sustituido por hidroxi, alcoxi, amino, alquilamino, dialquilamino, fenilo, nitrógeno y/u oxígeno u opcionalmente sustituido por un anillo de cicloalquilo C3-8 que contiene opcionalmentede1 a 3 heteroátomos y opcionalmente sustituido por alquilo C1-4; o Y es un grupodefórmula (i): en la que X es un enlaceoCH2; A es un anillo de piridina, pirimidina, tiazol, oxazol, tiofeno, furano o piridazina; R 1 es un grupo de fórmula (ii): en la que R 4 es hidrógeno, halógeno, alcoxi C1-3, alquiltio C1-3 o alquilo C1-3 (opcionalmente sustituido por uno o más átomos de fluor); R 5 es hidrógeno, hidroxi halógeno, alquiltio C1-3, alquilo C1-4 (opcionalmente sustituido por uno o más átomos de fluor), cicloalquilo C3-4, MeOCH2, MeSCH2, fenilo, piridilo o alcoxi C1-3; o R 4 y R 5 son -(CH2)ten el que t es 3 ó 4 que forman un anillo condensado; R 6 es hidrógeno, halógeno, alcoxi C1-3, alquiltio C1-3o alquilo C1-3 (opcionalmente sustituido por uno o más átomos de fluor); o R 5 y R 6 son -(CH2)ten el que t es 3 ó 4 que forman un anillo condensado; R 7 es hidrógeno, hidroxi, alcoxiC1-3, amino, hidroxi-alquilo C1-3, -NH-alquilo C1-3, -N-diaquilo C1-3, -N-H-cicloalquilo C3-8, -N-cicloalquilo C3-8, -NH-fenilo, -NH-alquilfenilo C1-3, (heterociclo)alquiloC1-3, (heterociclo)-alquiltioC1-3, (heterociclo)alquiloxiC1-3, (heterociclo)-alquilaminoC1-3, (heterociclo)tio-, (heterociclo)oxi-, (heterociclo)amino-, alquiltioC1-3, ciano, tiol, alquilo C1-3 (opcionalmente sustituido por uno o más átomos de fluor), -alquilamino C1-3, -alquilaminoalquilo C1-3, carboxamido-alquilo C1-3, acetoxi-alquilo C1-3, o cicloalquilo C3-4; S es1ó 2; B es un anillo de pirrol, tiofeno, furano, oxazol, tiazol, piridina, pirimidina, piridazina, pirazina o triazina; Z es -CH=CH-,-CH2CH2ó CH2O; R 2 es hidrógeno, NO2, NH2, N(alquilo C1-6)2, CO2H, CH2OH, halógeno, CO2-alquilo C1-6, alquilo C1-8 opcionalmente interrumpido poruno o más átomos de oxígeno, nitrógeno o azufre y opcionalmente sustituido por CO2H, o R 2 es hidroxi, imidazol-1-ilCH2, fenilo opcionalmente sustituido por CH2CO2H ó CONR 9 R 10 en el que R 9 y R 10 son independientemente hidrógeno, alquilo C1-6 opcionalmente sustituido por hidroxi CO2H y/u opcionalmente interrumpido por oxígeno, nitrógeno o azufre; R 3 es hidrógeno, R 11 CO2H, R 11 PO(OH)2, R 22 tetrazol-5-ilo, COR 13 , NR 14 R 15 , CH2NR 16 CH2CO2H, alquilo C1-8 opcionalmente interrumpido por uno o más átomos de oxígeno, azufre o nitrógeno y opcionalmente sustituido por CO2H, ó R 3 es un grupo de fórmula (iii): en la que D es un anillo saturado de 4, 5 ó 6 miembros que contiene un átomo de nitrógeno opcionalmente sustituido por hidroxi y sustituido por CO2H ó CONH-het en el que het es tetrazol-5-ilo o un anillo de tiazol o tiadiazol sustituido por CH2CO2H, o D es un anillo de fenilo o un anillo heterocíclico aromático de 5 miembros que contiene de1 a 3 heteroátomos seleccionados entre nitrógeno, oxígeno o azufre opcionalmente sustituido por uno o más grupos seleccionados entre CF3, CO2H, CH2OH, alquilo C1-6 opcionalmente interrumpido por uno o más átomos de oxígeno, (CH2)pCO2H, C(CO2H)=NOMe, tetrazol-5-ilo, CH2tetrazol-5-ilo, CH2CON(CH2CO2H)2 ó CH2COR 18 ; en los que R 11 es OCH2, (CH2)p, SCH2, CONHCH2, NHCH(R 19 ) ó NR 20 (CH2)p; R 12 es un enlace, (CH2)p, OCH2, SCH2, CONH, CONHCH2, CONHCH2CONH, NHCH2CONH, NHCH(R 9 ); R 13 es OH, N(CH2CO2H)2, NHS(O)2R 21 o un grupo de fórmula (iv): R 14 y R 15 son independientemente hidrógeno, CH2CO2H, CHPh2 ó C(=S)CH2CH2CO2H; R 16 es hidrógeno, alquilo C1-6 ó CO2CH2Ph; R 17 es un enlace, un átomo de azufre, un grupo CONH, CH2, CH2O, OCH2, un grupo-NR 22 CH(CO2H)CH2o un grupo CONR 22 (CH2)pCONR 23 ó NR 22 (CH2)pCONR 23 ; R 18 es un grupo de fórmula (iv) como se ha definido anteriormente o un grupo de fórmula (v): R 19 es hidrógeno, alquilo C1-6, opcionalmente sustituido por hidroxi y/u opcionalmente interrumpido por oxígeno, nitrógeno oazufre; R 20 es hidrógeno o alquilo C1-6; P es 1ó 2; R 21 es NH2 o alquilo C1-6 opcionalmente interrumpido por oxígeno o nitrógeno; R 22 y R 23 son independientemente hidrógeno o alquilo C1-6; y Q 1 y Q 2 representan cada uno independientemente un átomo de O ó S.
ES98957267T 1997-11-21 1998-11-18 Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores. Expired - Lifetime ES2172939T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704272A SE9704272D0 (sv) 1997-11-21 1997-11-21 Novel Compounds
SE9801397A SE9801397D0 (sv) 1998-04-21 1998-04-21 Novel compounds

Publications (1)

Publication Number Publication Date
ES2172939T3 true ES2172939T3 (es) 2002-10-01

Family

ID=26663136

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98957267T Expired - Lifetime ES2172939T3 (es) 1997-11-21 1998-11-18 Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.

Country Status (9)

Country Link
EP (1) EP1042320B1 (es)
JP (1) JP2001524480A (es)
AT (1) ATE213242T1 (es)
AU (1) AU1356299A (es)
DE (1) DE69803883T2 (es)
DK (1) DK1042320T3 (es)
ES (1) ES2172939T3 (es)
PT (1) PT1042320E (es)
WO (1) WO1999026944A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753595A (en) * 1995-08-31 1998-05-19 Fmc Corporation Herbicidal 3-(substituted benzoxazol-7-yl) and 3-(Substituted benzothiazol-7-yl)-1-substituted-6-trifluoromethyl-2 4-(1h 3h)pyrimidinediones
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
SE9702002D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
SE9702794D0 (sv) * 1997-07-24 1997-07-24 Astra Pharma Prod New compounds

Also Published As

Publication number Publication date
PT1042320E (pt) 2002-07-31
JP2001524480A (ja) 2001-12-04
DE69803883D1 (de) 2002-03-21
WO1999026944A1 (en) 1999-06-03
EP1042320B1 (en) 2002-02-13
AU1356299A (en) 1999-06-15
DE69803883T2 (de) 2002-09-19
EP1042320A1 (en) 2000-10-11
ATE213242T1 (de) 2002-02-15
DK1042320T3 (da) 2002-05-13

Similar Documents

Publication Publication Date Title
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
AUPO755097A0 (en) Receptor agonist and antagonist
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
NO972016D0 (no) Indolyl-Y-reseptorantagonister
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
ID16742A (id) Antagonis reseptor endotelin
SE9702651D0 (sv) Novel compounds
EA199900630A1 (ru) Антагонисты рецепторов витронектина
FI973047A (fi) AZA ja AZA(N-OXY)-analogit glysiini/NMDA-reseptoriantagonisteille
NO20004668D0 (no) 1-(3-heteroarylpropyl- eller -prop-2-enyl)-4- benzylpiperidiner anvendt som NMDA-reseptorantagonister
PT1036072E (pt) Antagonistas de receptores de trombina
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
ES2156444T3 (es) Nuevos compuestos.
SE9702794D0 (sv) New compounds
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
ID24468A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
BR9611521A (pt) Antagonistas de receptor de aminoácido excitador
EA200000197A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
ID24819A (id) TURUNAN ASAM α-HIDROSIKARBOKSILAT TERSUBSTITUSI SECARA HETEROSIKLIK, PEMBUATAN DAN PENGGUNAANNYA SEBAGAI ANTAGONIS RESEPTOR ENDOTELIN
ID22978A (id) Antagonis reseptor endotelin
EA199800204A1 (ru) Антагонисты 5-нтрецепторов для лечения дискинезии

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1042320

Country of ref document: ES